SecBot SecBot
SC 13G ·Filed Nov 5, 2026

CTNM

Contineum Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed11d 14h ago SEC0000315066-26-002728
Passive investor 5%+ stake
Actionable Insight • Neutral

The cluster of four passive 13G filings within 14 days suggests growing institutional interest in CTNM at current levels. Monitor for additional 13G filings or a potential 13D conversion if any holder crosses the 10% threshold or changes intent. The next catalyst is likely clinical data readouts for the PIPE-791 IPF program, which drove the 45% R&D expense increase in Q3.

DirectionNeutral
Confidencehigh
Horizonweeks

PIPE-791

● Neutral Named in this SC 13G
Impact
Phase
Phase 2
Time to market
At least 4-5 years away, if successful. The Phase 2 PROPEL-IPF trial is estimated to complete in June 2028, and a Phase 3 program and regulatory filing would follow, meaning potential approval is likely in the 2030-2032 timeframe at the earliest.
Next catalyst
None dated

What to watchPIPE-791 is a mid-stage asset with no near-term binary catalyst; the next major event is the Phase 2 PROPEL-IPF readout estimated for mid-2028. The competitive landscape shifted significantly on October 12, 2026, when BMS's admilparant succeeded in Phase 3 for IPF, potentially becoming the first approved LPAR1 antagonist. Investors should watch for enrollment completion updates and whether Contineum can differentiate PIPE-791 on safety, dosing convenience, or CNS indications (chronic pain, MS) where BMS's compound may not compete.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$8.81
T+0 close · Nov 5, 2026 · via day close
Latest settled
+11.01%
T+5 · $9.78
Vs SPY
+7.72%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $8.81entry
  2. T+1 · 11d ago +8.06%α +7.75% · $9.52
  3. T+5 · 5d ago +11.01%α +7.72% · $9.78
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

FMR LLC (Fidelity) disclosed a 7.9% passive stake in Contineum Therapeutics as of September 30, 2026, consisting of 2,610,247.50 shares of Class A common stock. This is a new 5%+ filing from Fidelity, adding to a cluster of recent passive stake disclosures by other institutional investors (Squadron Capital, Franklin Templeton, Trails Edge Capital) over the past two weeks. The filing certifies no intent to influence control, consistent with a routine passive investment by a major asset manager.

Key Financial Metrics

Stake
7.9%
Investor
FMR LLC (Fidelity)
Investor Type
mutual fund

Key Facts

  • FMR LLC (Fidelity) filed a Schedule 13G disclosing beneficial ownership of 2,610,247.50 shares of Contineum Therapeutics Class A common stock as of September 30, 2026.
  • The stake represents 7.9% of shares outstanding.
  • The filing certifies passive intent under Rule 13d-1(b) with no purpose of changing or influencing control.
  • This is a new 5%+ disclosure from Fidelity; no prior 13G or 13D from FMR LLC for CTNM appears in the cross-filing context.
  • The filing follows recent 13G filings by Squadron Capital (5.1%), Franklin Templeton (5.2%), and Trails Edge Capital (5.1%) over the past 14 days, creating a cluster of institutional passive stake disclosures.
  • Contineum is a pre-revenue clinical-stage biotech with a $365M market cap, $244.5M cash, and a net loss of $18.7M in Q3 2026.

Financial Impact

Fidelity's 7.9% stake valued at approximately $28.8M based on $365M market cap; no transaction price disclosed.

ownership concentration

Risk Factors

  • Fidelity's passive certification could change if it later engages with management or seeks board representation, requiring a conversion to Schedule 13D.
  • The company is pre-revenue with widening losses ($18.7M in Q3 2026 vs $12.8M in Q3 2025) and depends on successful clinical development of PIPE-791.
  • High volatility (9.8% normal daily move) amplifies price sensitivity to any news flow.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G Filing (Primary)0000315066-26-002728
Document: 0000315066-26-002728-index-headers.html0000315066-26-002728
Document: 0000315066-26-002728-index.html0000315066-26-002728
Document: 0000315066-26-002728.txt0000315066-26-002728

US Market Status

Market Closed · Opens in 5h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026